Anti Aging
Hair Growth
Muscle Growth
Peptide Blends
Peptide Supplies
Peptides
Skin
Testosterone
Weight Loss-
CJC-1295 10mg $90.00
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH) and growth hormone secretagogue (GHS) developed by ConjuChem Biotechnologies.
GHRH is a 44-amino acid long peptide which our hypothalamus synthesizes and in the pituitary gland, it binds to the growth hormone (GH) receptors, resulting in the release, regulation and pulsatile secretion of GH.
We already talked about GH therapy as being FDA approved in conditions such as GH deficiency, Turner syndrome, Prader-Willi syndrome, idiopathic short stature etc. Recombinant human GH treatment is generally performed as one daily, subcutaneous injection which elevates the levels of GH serum in the blood.
One of the major problems with this approach to treatment is that the efficacy of GH therapy is hard to determine due to the lack of biological serum biomarkers. Currently, most facilities are using levels of IGF-1 and IGFBP-3 to monitor the efficacy of this therapy but these levels may vary wildly (due to growth velocity, glucose tolerance, insulin levels etc.).
Furthermore, GH abuse extended across multiple sports disciplines, making it even harder to suppress and put this problem under control.
Researchers hope to solve this problem by employing new biomarkers of GH action and secretion. One such way is to employ newly developed molecules, such as CJC-1295, shown to increase both GH and IGF-1 levels in the blood, without affecting the pulsatility of GH secretion. CJC-1295 also has a prolonged half-life of 8 to 10 days, due to its ability to bind to the endogenous serum albumin.
So, what scientists are hoping to achieve with CJC-1295 is both a safe way of promoting GH secretion as well as making it measurable in a laboratory setting. There were numerous studies tackling this issue, but we still need further testing to confirm these preliminary findings.
Reference:
Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Horm IGF Res. 2009 Dec;19(6):471-7. doi: 10.1016/j.ghir.2009.03.001. Epub 2009 Apr 21. PMID: 19386527; PMCID: PMC2787983.
-
CJC-1295, Ipamorelin $100.00
CJC-1295 and Ipamorelin peptide are often used in conjunction as their action is synergistic and more than doubly effective. PeptideShop.com offers this blend in a total quantity of 10mg (5mg each).
CJC-1295 Peptide
CJC-1295 is a synthetic hormone-releasing hormone analogue and growth hormone secretagogue. It was developed by ConjuChem Biotechnologies as a means to promote regulation and pulsatile GH secretion. GH therapy is an FDA approved way of treating its deficiencies, diseases such as Turner or Prader-Willi syndrome, idiopathic short stature etc.
The only problem with this approach to treatment is it might be problematic to determine the effectiveness of these therapies due to lacks of biological serum markers. CJC-1295 peptide was developed to mitigate these problems and uncover a more potent and measurable way of secreting GH without affecting its pulsatile nature.
Ipamorelin Peptide
Ipamorelin is also a growth hormone secretagogue, but it also acts as a ghrelin hormone secretagogue receptor agonist, as demonstrated in both in vitro and in vivo studies. Even though its effect is similar to that of CJC-1295, the interesting thing about Ipamorelin is that it does not raise ACTH (Adrenocorticotropic hormone), or cortisol levels for that matter, making it the first GHTP receptor agonist with selective GH release ability.
CJC-1295 And Ipamorelin Peptide Blend
Rather than administering one peptide or the other, more and more research is aimed at testing out the synergistic effect of these two peptides. Some studies showed a 3 or even 5 fold increase in growth hormone secretion increase!
Both CJC-1295 and Ipamorelin will stimulate the pituitary gland to increase GH production and release more hormones through the bloodstream. Animal studies also demonstrated significant ghrelin stimulation, resulting in food intake, fat deposition and muscle building control.
Despite seeing these beneficial results in both GH secretion and appetite regulation, this therapy is still not an FDA approved treatment, as most of our data comes from animal studies. Definitive human studies are needed before moving into the realm of human consumption.
References:
